Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 3/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5842899 | 0.90 | CRHR1 (0.62) | CRHR1 | |
| SCHEMBL5844077 | 0.89 | CRHR1 (0.60) | CRHR1 | |
| SCHEMBL30397878 | 0.87 | CRHR1 (1.00) | CRHR1 | |
| SCHEMBL123421 | 0.87 | CRHR1 (1.00) | CRHR1 | |
| Hydrochloric Acid SCHEMBL3103253 | 0.86 | CRHR1 (0.97) | CRHR1 | |
| SCHEMBL5843968 | 0.85 | CRHR1 (0.73) | CRHR1 | |
| SCHEMBL5842692 | 0.85 | CRHR1 (0.77) | CRHR1 | |
| SCHEMBL5844629 | 0.85 | CRHR1 (0.77) | CRHR1 | |
| SCHEMBL5844221 | 0.85 | CRHR1 (0.77) | CRHR1 | |
| Hydrochloric Acid SCHEMBL3103251 | 0.85 | CRHR1 (0.95) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6387894-B1 | MIXTURE OF CORTICOTROPIN RELEASING FACTOR ANTAGINIST AND RENIN-ANGIOTENSIN SYSTEM INHIBITOR; THERAPY FOR CONGESTIVE HEART FAILURE, HYPOTENSIVE AGENTS | PFIZER INC. | 2002-05-14 | — | — | US | claimed |
| US-6384039-B1 | ADMINISTERING CORTICOTROPIN RELEASING FACTOR ANTAGONIST | PFIZER INC. | 2002-05-07 | — | — | US | claimed |
| US-20010000340-A1 | New uses for corticotropin releasing factor antagonists | CHEN YUHPYNG L (US) | 2001-04-19 | — | — | US | claimed |
| EP-1059100-A2 | Combinations of CRF antagonists and renin-angiotensin system inhibitors | Pfizer Products Inc. (US) | 2000-12-13 | — | — | EP | claimed |
| EP-1040831-A2 | Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death | Pfizer Products Inc. (US) | 2000-10-04 | — | — | EP | claimed |
| EP-0764166-B1 | CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | PFIZER (US) | 2000-09-13 | — | — | EP | claimed |
| EP-0764166-A1 | CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | PFIZER INC. (US) | 1997-03-26 | — | — | EP | claimed |
| WO-1995033750-A1 | CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | PFIZER INC. (US) | 1995-12-14 | — | — | WO | claimed |
| US-7125880-B1 | Corticotropin releasing factor antagonists | PFIZER INC. (US) | 2006-10-24 | — | — | US | disclosed |
| US-7067664-B1 | Corticotropin releasing factor antagonists | PFIZER INC. (US) | 2006-06-27 | — | — | US | disclosed |
| US-6992188-B1 | Substituted heterocyclic derivatives | PFIZER, INC. (US) | 2006-01-31 | — | — | US | disclosed |
| US-20050247913-A1 | Phosphorous ester compound, process for producing the same, and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-11-10 | — | — | US | disclosed |
| US-6956047-B1 | Corticotropin releasing factor antagonists | PFIZER INC. (US) | 2005-10-18 | — | — | US | disclosed |
| US-20050032846-A1 | Corticotropin releasing factor antagonists | PFIZER INC. | 2005-02-10 | — | — | US | disclosed |
| US-5962479-A | Corticotropin releasing factor antagonists | PFIZER INC. (US) | 1999-10-05 | — | — | US | disclosed |
| EP-0920429-A1 | SUBSTITUTED PYRIDO- OR PYRIMIDO-CONTAINING 6,6- OR 6,7-BICYCLIC DERIVATIVES | PFIZER INC. (US) | 1999-06-09 | — | — | EP | disclosed |
| WO-1998005661-A1 | SUBSTITUTED PYRIDO- OR PYRIMIDO-CONTAINING 6,6- OR 6,7-BICYCLIC DERIVATIVES | PFIZER INC. (US) | 1998-02-12 | — | — | WO | disclosed |
| EP-0778277-A1 | Substituted heterocyclic derivatives as CRF antagonists | PFIZER INC. (US) | 1997-06-11 | — | — | EP | disclosed |
| EP-0764166-A1 | CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | PFIZER INC. (US) | 1997-03-26 | — | — | EP | disclosed |
| WO-1995033750-A1 | CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | PFIZER INC. (US) | 1995-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010000340-A1 | New uses for corticotropin releasing factor antagonists | CRH, CRHR1, CRHR2 | CRHR1 2/4885 |
| US-20050032846-A1 | Corticotropin releasing factor antagonists | CRH, CRHR2, CRHR1 | CRHR1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.